Publications

• The prevalence and clinical significance of residual occult breast cancer after neoadjuvant chemotherapy: reassessing surgical pathology in cases initially described as pathological complete response.
  Histopathology Volume: 86 Page(s): 1112 - 1120
  06/01/2025 Authors: Ai D; Arrey EN; Postlewait LM; Gao Y; Li X
• Clinicopathologic and Whole Exome Sequencing Analyzes of High-Grade Serous Carcinoma-Like Carcinoma of the Breast Reveal Unique Genetic Profile and Poor Clinical Outcome.
  Am J Surg Pathol
  05/23/2025 Authors: Hsiao W-Y; Nguyen TTA; Yang W; Yan H; Li Z; Zhang L; Yang J; Li X
• Malignant phyllodes tumours of the breast: the case for revising WHO's 'full house' diagnostic criteria.
  Histopathology
  04/13/2025 Authors: Tan PH; Ellis IO; Allison KH; Badve SS; Brogi E; Callagy G; Charafe-Jauffret E; Chen C-J; Chen Y-Y; Collins LC
• Low interobserver agreement among subspecialised breast pathologists in evaluating HER2-low breast cancer.
  J Clin Pathol Volume: 77 Page(s): 815 - 821
  11/19/2024 Authors: Turashvili G; Gao Y; Ai DA; Ewaz AM; Gjeorgjievski SG; Wang Q; Nguyen TTA; Zhang C; Li X
• Tumor NOS2 and COX2 Spatial Juxtaposition with CD8+ T Cells Promote Metastatic and Cancer Stem Cell Niches that Lead to Poor Outcome in ER- Breast Cancer.
  Cancer Res Commun Volume: 4 Page(s): 2766 - 2782
  10/01/2024 Authors: Ridnour LA; Heinz WF; Cheng RYS; Wink AL; Kedei N; Pore M; Imtiaz F; Femino EL; Gonzalez AL; Coutinho LL
• Validation Study of the Newly Proposed Refined Diagnostic Criteria for Malignant Phyllodes Tumor With 136 Borderline and Malignant Phyllodes Tumor Cases.
  Am J Surg Pathol Volume: 48 Page(s): 1146 - 1153
  09/01/2024 Authors: Li X; Nguyen TTA; Zhang J; Nayak A; Liu Y; Duckworth LA; Zhang G; Bakkar R; Agarwal I; Hou Y
• Breast Cancer With HER2 Immunohistochemical Score 2 and Average HER2 Signals/Cell 6 or More and HER2/CEP17 Ratio Less Than 2 ('ISH Group 3'): A Multi-Institutional Cohort Analysis Emphasizing Outcome and Molecular Subtype.
  Mod Pathol Volume: 37 Page(s): 100530
  08/01/2024 Authors: Ajabnoor R; Zhang G; Hu Y; Gao Y; Finkelman BS; Turner BM; Yi S; Dhakal A; Audeh W; Li Z
• Training pathologists to assess stromal tumour-infiltrating lymphocytes in breast cancer synergises efforts in clinical care and scientific research.
  Histopathology Volume: 84 Page(s): 915 - 923
  05/01/2024 Authors: Ly A; Garcia V; Blenman KRM; Ehinger A; Elfer K; Hanna MG; Li X; Peeters DJE; Birmingham R; Dudgeon S
• High tumor infiltrating lymphocytes are significantly associated with pathological complete response in triple negative breast cancer treated with neoadjuvant KEYNOTE-522 chemoimmunotherapy.
  Breast Cancer Res Treat Volume: 205 Page(s): 193 - 199
  05/01/2024 Authors: Wood SJ; Gao Y; Lee J-H; Chen J; Wang Q; Meisel JL; Li X
• Reproducible Reporting of the Collection and Evaluation of Annotations for Artificial Intelligence Models.
  Mod Pathol Volume: 37 Page(s): 100439
  04/01/2024 Authors: Elfer K; Gardecki E; Garcia V; Ly A; Hytopoulos E; Wen S; Hanna MG; Peeters DJE; Saltz J; Ehinger A
• Subspecialized breast pathologists have suboptimal interobserver agreement in Ki-67 evaluation using 20% as the cutoff.
  Breast Cancer Res Treat Volume: 204 Page(s): 415 - 422
  04/01/2024 Authors: Ai D; Turashvili G; Gjeorgjievski SG; Wang Q; Ewaz AM; Gao Y; Nguyen T; Zhang C; Li X
• Image-based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno-oncology Biomarker Working Group on Breast Cancer.
  J Pathol Volume: 262 Page(s): 271 - 288
  03/01/2024 Authors: Jahangir CA; Page DB; Broeckx G; Gonzalez CA; Burke C; Murphy C; Reis-Filho JS; Ly A; Harms PW; Gupta RR
• Correlation of HER2 Protein Level With mRNA Level Quantified byRNAscope in Breast Cancer.
  Mod Pathol Volume: 37 Page(s): 100408
  02/01/2024 Authors: Li X; Lee J-H; Gao Y; Zhang J; Bates KM; Rimm DL; Zhang H; Smith GH; Lawson D; Meisel J
• NOS2 and COX2 Provide Key Spatial Targets that Determine Outcome in ER- Breast Cancer.
  bioRxiv
  12/23/2023 Authors: Ridnour LA; Heinz WF; Cheng RY; Wink AL; Kedei N; Pore M; Imtiaz F; Femino EL; Gonzalez AL; Coutinho L
• Spatial analysis of NOS2 and COX2 interaction with T-effector cells reveals immunosuppressive landscapes associated with poor outcome in ER- breast cancer patients.
  bioRxiv
  12/23/2023 Authors: Ridnour LA; Cheng RYS; Heinz WF; Pore M; Gonzalez AL; Femino EL; Moffat R; Wink AL; Imtiaz F; Coutinho L
• Rosai-Dorfman disease of the breast: a clinicoradiologic and pathologic study.
  Hum Pathol Volume: 141 Page(s): 30 - 42
  11/01/2023 Authors: Wang Q; Bradley K; Zhang M; Li S; Li X
• Low-grade adenosquamous carcinoma of the breast: aclinical, morphological and immunohistochemical analysisof 25 patients.
  Histopathology Volume: 83 Page(s): 252 - 263
  08/01/2023 Authors: Lewis G; Fong N; Gjeorgjievski SG; Li XB; Li Z; Wei S; Sturgis CD; Wang C; Komforti M; Zhang H
• Interferon-gamma is quintessential for NOS2 and COX2 expression in ER- breast tumors that lead to poor outcome.
  Cell Death Dis Volume: 14 Page(s): 319
  05/11/2023 Authors: Cheng RYS; Ridnour LA; Wink AL; Gonzalez AL; Femino EL; Rittscher H; Somasundaram V; Heinz WF; Coutinho L; Rangel MC
• The Role of Artificial Intelligence in Accurate Interpretation of HER2 Immunohistochemical Scores 0 and 1+ in Breast Cancer.
  Mod Pathol Volume: 36 Page(s): 100054
  03/01/2023 Authors: Wu S; Yue M; Zhang J; Li X; Li Z; Zhang H; Wang X; Han X; Cai L; Shang J
• Clinicopathologic Predictors of Clinical Outcomes in Mammary Adenoid Cystic Carcinoma: A Multi-institutional Study.
  Mod Pathol Volume: 36 Page(s): 100006
  02/01/2023 Authors: Khoury T; Rosa M; Nayak A; Karabakhtsian R; Fadare O; Li Z; Turner B; Fang Y; Kumarapeli A; Li X
• PLK1 and AURKB phosphorylate survivin differentially to affect proliferation in racially distinct triple-negative breast cancer.
  Cell Death Dis Volume: 14 Page(s): 12
  01/10/2023 Authors: Garlapati C; Joshi S; Bhattarai S; Krishnamurthy J; Turaga RC; Nguyen T; Li X; Aneja R
• Inhibition of NADPH Oxidase-ROS Signal using Hyaluronic Acid Nanoparticles for Overcoming Radioresistance in Cancer Therapy.
  ACS Nano Volume: 16 Page(s): 18708 - 18728
  11/22/2022 Authors: Zhu L; Zhao Y; Liu T; Chen M; Qian WP; Jiang B; Barwick BG; Zhang L; Styblo TM; Li X
• A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and In Situ Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer.
  Clin Cancer Res Volume: 28 Page(s): 4392 - 4401
  10/14/2022 Authors: Sun K; Xu Y; Zhang L; Niravath P; Darcourt J; Patel T; Teh BS; Farach AM; Guerrero C; Mathur S
• Updates on Lobular Neoplasms and Papillary, Adenomyoepithelial, and Fibroepithelial Lesions of the Breast.
  Arch Pathol Lab Med Volume: 146 Page(s): 930 - 939
  08/01/2022 Authors: Li X; Febres-Aldana C; Zhang H; Zhang X; Uraizee I; Tang P
• Pilot study to evaluate tools to collect pathologist annotations for validating machine learning algorithms.
  J Med Imaging (Bellingham) Volume: 9 Page(s): 047501
  07/01/2022 Authors: Elfer K; Dudgeon S; Garcia V; Blenman K; Hytopoulos E; Wen S; Li X; Ly A; Werness B; Sheth MS
• Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer.
  Clin Cancer Res Volume: 28 Page(s): 2878 - 2889
  07/01/2022 Authors: Yam C; Abuhadra N; Sun R; Adrada BE; Ding Q-Q; White JB; Ravenberg EE; Clayborn AR; Valero V; Tripathy D
• Dedifferentiation-mediated stem cell niche maintenance in early-stage ductal carcinoma in situ progression: insights from a multiscale modeling study.
  Cell Death Dis Volume: 13 Page(s): 485
  05/21/2022 Authors: Butner JD; Dogra P; Chung C; Ruiz-Ramrez J; Nizzero S; Plodinec M; Li X; Pan P-Y; Chen S-H; Cristini V
• Development of Training Materials for Pathologists to Provide Machine Learning Validation Data of Tumor-Infiltrating Lymphocytes in Breast Cancer.
  Cancers (Basel) Volume: 14
  05/17/2022 Authors: Garcia V; Elfer K; Peeters DJE; Ehinger A; Werness B; Ly A; Li X; Hanna MG; Blenman KRM; Salgado R
• Utility of Oncotype DX score in clinical management for T1 estrogen receptor positive, HER2 negative, and lymph node negative breast cancer.
  Breast Cancer Res Treat Volume: 192 Page(s): 509 - 516
  04/01/2022 Authors: Nguyen TTA; Postlewait LM; Zhang C; Meisel JL; O'Regan R; Badve S; Kalinsky K; Li X
• Deep Learning-Based Pathology Image Analysis Enhances Magee Feature Correlation With Oncotype DX Breast Recurrence Score.
  Front Med (Lausanne) Volume: 9 Page(s): 886763
  01/01/2022 Authors: Li H; Wang J; Li Z; Dababneh M; Wang F; Zhao P; Smith GH; Teodoro G; Li M; Kong J
• The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group.
  NPJ Breast Cancer Volume: 7 Page(s): 150
  12/01/2021 Authors: El Bairi K; Haynes HR; Blackley E; Fineberg S; Shear J; Turner S; de Freitas JR; Sur D; Amendola LC; Gharib M
• Molecular Classification of Triple Negative Breast Cancer and the Emergence of Targeted Therapies.
  Clin Breast Cancer Volume: 21 Page(s): 509 - 520
  12/01/2021 Authors: Sakach E; O'Regan R; Meisel J; Li X
• The Incidence of Occult Malignant and High-Risk Pathologic Findings in Breast Reduction Specimens.
  Plast Reconstr Surg Volume: 148 Page(s): 534e - 539e
  10/01/2021 Authors: Razavi SA; Hart AM; Betarbet U; Li X; Carlson GW; Losken A
• Prognostic value of androgen receptor expression and molecular alterations in metastatic triple-negative or low hormone receptor breast carcinomas.
  Hum Pathol Volume: 116 Page(s): 73 - 81
  10/01/2021 Authors: Shen T; Wei L; Li X; Parwani AV; Li Z
• Pan-cancer analysis of pathway-based gene expression pattern at the individual level reveals biomarkers of clinical prognosis.
  Cell Rep Methods Volume: 1
  08/23/2021 Authors: Su K; Yu Q; Shen R; Sun S-Y; Moreno CS; Li X; Qin ZS
• ANETT: PhAse II trial of NEoadjuvant TAK-228 plus Tamoxifen in patients with hormone receptor-positive breast cancer.
  Breast Cancer Res Treat Volume: 188 Page(s): 433 - 439
  07/01/2021 Authors: Koca E; Niravath PA; Ensor J; Patel TA; Li X; Hemati P; Wong H; Qian W; Boone T; Zhao J
• Management of high-risk breast lesions diagnosed on core biopsies and experiences from prospective high-risk breast lesion conferences at an academic institution.
  Breast Cancer Res Treat Volume: 185 Page(s): 573 - 581
  02/01/2021 Authors: Li X; Ma Z; Styblo TM; Arciero CA; Wang H; Cohen MA
• Expression of tdTomato and luciferase in a murine lung cancer alters the growth and immune microenvironment of the tumor.
  PLoS One Volume: 16 Page(s): e0254125
  01/01/2021 Authors: Huang L; Bommireddy R; Munoz LE; Guin RN; Wei C; Ruggieri A; Menon AP; Li X; Shanmugam M; Owonikoko TK
• Magee Equations and response to neoadjuvant chemotherapy in ER+/HER2-negative breast cancer: a multi-institutional study.
  Volume: 34 Page(s): 77 - 84
  01/01/2021 Authors: Bhargava R; Esposito NN; OConnor SM; Li Z; Turner BM; Moisini I; Ranade A; Harris RP; Miller DV; Li X
• Different Breast Cancer Subtypes Show Different Metastatic Patterns: A Study from A Large Public Database.
  Asian Pac J Cancer Prev Volume: 21 Page(s): 3587 - 3593
  12/01/2020 Authors: Guo Y; Arciero CA; Jiang R; Behera M; Peng L; Li X
• A comprehensive overview of metaplastic breast cancer: clinical features and molecular aberrations.
  Breast Cancer Res Volume: 22 Page(s): 121
  11/04/2020 Authors: Reddy TP; Rosato RR; Li X; Moulder S; Piwnica-Worms H; Chang JC
• Triple-negative apocrine carcinoma: A rare pathologic subtype with a better prognosis than other triple-negative breast cancers.
  J Surg Oncol Volume: 122 Page(s): 1232 - 1239
  11/01/2020 Authors: Arciero CA; Diehl AH; Liu Y; Sun Q; Gillespie T; Li X; Subhedar P
• Patients with benign papilloma diagnosed on core biopsies and concordant pathology-radiology findings can be followed: experiences from multi-specialty high-risk breast lesion conferences in an academic center.
  Breast Cancer Res Treat Volume: 183 Page(s): 577 - 584
  10/01/2020 Authors: Ma Z; Arciero CA; Styblo TM; Wang H; Cohen MA; Li X
• Evaluation of PD-L1, tumor-infiltrating lymphocytes, and CD8+and FOXP3+immune cells in HER2-positive breast cancer treated with neoadjuvant therapies.
  Breast Cancer Res Treat Volume: 183 Page(s): 599 - 606
  10/01/2020 Authors: Zhao J; Meisel J; Guo Y; Nahta R; Hsieh KL; Peng L; Wei Z; O'Regan R; Li X
• Lack of HER4 signaling predicts poor prognosis among triple-negative breast cancer patients of African descent: A multi-institutional study
  Volume: 29
  06/01/2020 Authors: Wright N; Lee C; Krishnamurti U; Li X; Sahoo B; Green A; Ellis I; Agboola A; Wei G; McCullough L
• Quantitative digital imaging analysis of HER2 immunohistochemistry predicts the response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma.
  Breast Cancer Res Treat Volume: 180 Page(s): 321 - 329
  04/01/2020 Authors: Li AC; Zhao J; Zhao C; Ma Z; Hartage R; Zhang Y; Li X; Parwani AV
• Magee Equations (TM) and Response to Neoadjuvant Chemotherapy in ER+/HER2-Negative Breast Cancer: A Multi-Institutional Validation Study
  Volume: 33 Page(s): 115 - 116
  03/01/2020 Authors: Bhargava R; Esposito N; O'Connor S; Li Z; Turner B; Moisini I; Ranade A; Miller D; Li X; Moosavi H
• Benign High-Risk Breast Lesions can Avoid Unnecessary Surgery: A Prospective Study
  Volume: 100 Page(s): 204 - 205
  03/01/2020 Authors: Ma Z; Arciero C; Styblo TM; Wang H; Cohen M; Li X
• Patients with Benign Papilloma Diagnosed on Core Biopsies and Concordant Pathology-Radiology Findings can be Followed: A Prospective Study
  Volume: 33 Page(s): 204 - 204
  03/01/2020 Authors: Ma Z; Arciero C; Styblo TM; Wang H; Cohen M; Li X
• Patients with Benign Papilloma Diagnosed on Core Biopsies and Concordant Pathology-Radiology Findings can be Followed: A Prospective Study
  Volume: 100 Page(s): 204 - 204
  03/01/2020 Authors: Ma Z; Arciero C; Styblo TM; Wang H; Cohen M; Li X
• Benign High-Risk Breast Lesions can Avoid Unnecessary Surgery: A Prospective Study
  Volume: 33 Page(s): 204 - 205
  03/01/2020 Authors: Ma Z; Arciero C; Styblo TM; Wang H; Cohen M; Li X
• Papilloma diagnosed on core biopsies has a low upgrade rate.
  Clin Imaging Volume: 60 Page(s): 67 - 74
  03/01/2020 Authors: Li X; Aho M; Newell MS; Clifford K; Patel JG; Jou S; Cohen MA
• Combined HER3-EGFR score in triple-negative breast cancer provides prognostic and predictive significance superior to individual biomarkers.
  Sci Rep Volume: 10 Page(s): 3009
  02/20/2020 Authors: Ogden A; Bhattarai S; Sahoo B; Mongan NP; Alsaleem M; Green AR; Aleskandarany M; Ellis IO; Pattni S; Li XB
• The clinical significance of metastatic breast carcinoma to intramammary lymph node.
  Breast J Volume: 26 Page(s): 197 - 205
  02/01/2020 Authors: Khoury T; Fang Y; Karabakhtsian R; Mokhtar Desouki M; Nayak A; Hanna M; Sanati S; Peng X; Yan L; Li X
• Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2-Directed Chemotherapy in HER2-Positive Breast Cancer.
  Clin Breast Cancer Volume: 20 Page(s): 19 - 24
  02/01/2020 Authors: Meisel JL; Zhao J; Suo A; Zhang C; Wei Z; Taylor C; Aneja R; Krishnamurti U; Li Z; Nahta R
• A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study).
  Breast Cancer Res Volume: 21 Page(s): 100
  09/02/2019 Authors: Patel TA; Ensor JE; Creamer SL; Boone T; Rodriguez AA; Niravath PA; Darcourt JG; Meisel JL; Li X; Zhao J
• ER+/HER2+ Breast Cancer Has Different Metastatic Patterns and Better Survival Than ER-/HER2+ Breast Cancer.
  Clin Breast Cancer Volume: 19 Page(s): 236 - 245
  08/01/2019 Authors: Arciero CA; Guo Y; Jiang R; Behera M; O'Regan R; Peng L; Li X
• Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study.
  Cancers (Basel) Volume: 11
  07/17/2019 Authors: Bhattarai S; Klimov S; Mittal K; Krishnamurti U; Li XB; Oprea-Ilies G; Wetherilt CS; Riaz A; Aleskandarany MA; Green AR
• Use of Everolimus and Trastuzumab in Addition to Endocrine Therapy in Hormone-Refractory Metastatic Breast Cancer.
  Clin Breast Cancer Volume: 19 Page(s): 188 - 196
  06/01/2019 Authors: Paplomata E; Zelnak A; Santa-Maria CA; Liu Y; Gogineni K; Li X; Moreno CS; Chen Z; Kaklamani V; O'Regan RM
• Open label, phase II trial of neoadjuvant TAK-228 plus tamoxifen in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor type 2 (HER2)-negative breast cancer-ANETT.
  Volume: 37
  05/20/2019 Authors: Koca E; Niravath PA; Ensor J; Patel TA; Li X; Hemati P; Wong H; Qian W; Boone T; Zhao J
• The FDA-Approved Breast Cancer HER2 Evaluation Kit (HercepTest; Dako) May Miss Some HER2-Positive Breast Cancers.
  Am J Clin Pathol Volume: 151 Page(s): 504 - 510
  04/02/2019 Authors: Schneider F; Jin Y; Van Smaalen K; Gulbahce EH; Factor RE; Li X
• HER2 Immunohistochemistry Positivity is Strongly Predictive of HER2 Positive Breast Cancer Response to Neoadjuvant Therapy
  Volume: 32
  03/01/2019 Authors: Zhao J; Meisel J; Suo A; Zhang C; Wei Z; Aneja R; Li Z; Nahta R; Li X
• HER2 Immunohistochemistry Positivity is Strongly Predictive of HER2 Positive Breast Cancer Response to Neoadjuvant Therapy
  Volume: 32
  03/01/2019 Authors: Zhao J; Zhang C; Suo A; Shi Q; Wei Z; Li Z; Krishnamurti U; Li X
• Predictive Biomarker of Response to Neoadjuvant Therapy in HER2 Positive Breast Cancer
  Volume: 99
  03/01/2019 Authors: Zhao J; Meisel J; Suo A; Zhang C; Wei Z; Aneja R; Li Z; Nahta R; Li X
• Evaluation of tumor infiltrating lymphocyte, CD8+and FOXP3+cells and PD-L1 expression in tumor response to neoadjuvant therapy in HER2 positive breast cancer
  Volume: 32
  03/01/2019 Authors: Li X; Zhao J; Guo Y; Schneider F; Peng L; Aneja R; Meisel J; Nahta R
• HER2 Immunohistochemistry Positivity is Strongly Predictive of HER2 Positive Breast Cancer Response to Neoadjuvant Therapy
  Volume: 99
  03/01/2019 Authors: Zhao J; Zhang C; Suo A; Shi Q; Wei Z; Li Z; Krishnamurti U; Li X
• Predictive Value of HER2 Fluorescence In Situ Hybridization (FISH) Result in HER2 Positive Breast Cancer Response to Neoadjuvant Therapy
  Volume: 32
  03/01/2019 Authors: Zhao J; Suo A; Zhang C; Shi Q; Wei Z; Li Z; Li X
• Predictive Value of HER2 Fluorescence In Situ Hybridization (FISH) Result in HER2 Positive Breast Cancer Response to Neoadjuvant Therapy
  Volume: 99
  03/01/2019 Authors: Zhao J; Suo A; Zhang C; Shi Q; Wei Z; Li Z; Li X
• Percentage of HER2 immunohistochemistry complete membrane staining is not significantly associated with response to neoadjuvant therapy in HER2 positive breast cancer
  Volume: 99
  03/01/2019 Authors: Li X; Zhao J; Zhang C; Li Z
• Evaluation of tumor infiltrating lymphocyte, CD8+and FOXP3+cells and PD-L1 expression in tumor response to neoadjuvant therapy in HER2 positive breast cancer
  Volume: 99
  03/01/2019 Authors: Li X; Zhao J; Guo Y; Schneider F; Peng L; Aneja R; Meisel J; Nahta R
• Percentage of HER2 immunohistochemistry complete membrane staining is not significantly associated with response to neoadjuvant therapy in HER2 positive breast cancer
  Volume: 32
  03/01/2019 Authors: Li X; Zhao J; Zhang C; Li Z
• Significance of Classifying Breast Papillary Carcinoma Diagnosed on Core Biopsy
  Volume: 99
  03/01/2019 Authors: Van Smaalen K; Len K; Li X
• Significance of Classifying Breast Papillary Carcinoma Diagnosed on Core Biopsy
  Volume: 32
  03/01/2019 Authors: Van Smaalen K; Len K; Li X
• Breast Papillary Carcinoma Diagnosed on Core Biopsy has High Upgrade Rate to Invasive Carcinoma on Excision
  Volume: 99
  03/01/2019 Authors: Van Smaalen K; Len K; Li X
• Breast Papillary Carcinoma Diagnosed on Core Biopsy has High Upgrade Rate to Invasive Carcinoma on Excision
  Volume: 32
  03/01/2019 Authors: Van Smaalen K; Len K; Li X
• Care 001: multi-center randomized open-label phase II trial of neoadjuvant trastuzumab emtansine (T-DM1) in combination with lapatinib and nab-paclitaxel compared with paclitaxel, trastuzumab and pertuzumab in HER2-neu over-expressed breast cancer patients (TEAL study)
  Volume: 79
  02/01/2019 Authors: Creamer SL; Patel TA; Ensor JE; Rodriguez AA; Niravath PA; Darcourt JG; Kaklamani VG; Meisel JL; Li X; Zhao J
• Clinicopathologic factors associated with pCR to neoadjuvant anti-HER2-directed chemotherapy
  Volume: 79
  02/01/2019 Authors: Meisel JL; Suo A; Taylor CE; Zhang C; Li X
• Comparing breast biomarker status between routine immunohistochemistry and FISH studies and Oncotype DX testing, a study of 610 cases.
  Breast J Volume: 24 Page(s): 889 - 893
  11/01/2018 Authors: Neely C; You S; Mendoza PM; Aneja R; Sahin AA; Li X
• Magee Equation Recurrence Score Is Associated With Distal Metastatic Risk in Male Breast Carcinomas: Experience From Two Institutions.
  Am J Clin Pathol Volume: 150 Page(s): 491 - 498
  10/24/2018 Authors: Hou Y; Moosavi HS; Wei L; Parwani AV; Li XB; Li Z
• Evaluation of Prognosis in Hormone Receptor-Positive/HER2-Negative and Lymph Node-Negative Breast Cancer With Low Oncotype DX Recurrence Score.
  Clin Breast Cancer Volume: 18 Page(s): 347 - 352
  10/01/2018 Authors: Meisel J; Zhang C; Neely C; Mendoza P; You S; Han T; Liu Y; Sahin AA; O'Regan R; Li X
• Validation of the newly proposed American Joint Committee on Cancer (AJCC) breast cancer prognostic staging group and proposing a new staging system using the National Cancer Database.
  Breast Cancer Res Treat Volume: 171 Page(s): 303 - 313
  09/01/2018 Authors: Li X; Zhang Y; Meisel J; Jiang R; Behera M; Peng L
• Differences in tumor-infiltrating lymphocytes between racially distinct triple-negative breast tumors.
  Volume: 27 Page(s): 47 - 47
  07/01/2018 Authors: Wright N; Lee C; Wei G; Krishnamurti U; Li X; Rida PCG; Osan R; Aneja R
• Care 001: Multicenter randomized open label phase II trial of neoadjuvant trastuzumabemtansine (T-DM1) in combination with lapatinib and nab-paclitaxel compared with paclitaxel, trastuzumab and pertuzumab in HER 2 neu over-expressed breast cancer patients (TEAL study)
  Volume: 36
  05/20/2018 Authors: Patel TA; Ensor J; Creamer S; Rodriguez AA; Niravath PA; Darcourt JG; Kaklamani VG; Meisel JL; Li X; Kuhn JG
• A Nomogram for Predicting the Likelihood of Additional Axillary Nodal Metastases in Breast Cancer Patients with a Positive Intramammary Lymph Node
  Volume: 98 Page(s): 79 - 79
  03/01/2018 Authors: Khoury T; Karabakhtsian RG; Nayak A; Hanna MG; Fang Y; Peng X; Yan L; Li X; Fadare O; Ambrosone C
• The Clinical Significance of Metastatic Breast Carcinoma to Intra-Mammary Lymph Node
  Volume: 98 Page(s): 79 - 79
  03/01/2018 Authors: Khoury T; Hanna MG; Nayak A; Desouki MM; Sanati S; Fang Y; Li X; Peng X; Yan L; Fadare O
• Folate Receptor- alpha (FR alpha), Glycoprotein Nonmetastatic Melanoma B (GPNMB), BRCA1 Associated Protein (BAP1) and beta-Catenin Are Highly Expressed in Triple Negative Breast Carcinoma
  Volume: 98 Page(s): 82 - 82
  03/01/2018 Authors: Krishnamurti U; Yang J; Peng L; Cohen C; Li X
• A Nomogram for Predicting the Likelihood of Additional Axillary Nodal Metastases in Breast Cancer Patients with a Positive Intramammary Lymph Node
  Volume: 31 Page(s): 79 - 79
  03/01/2018 Authors: Khoury T; Karabakhtsian RG; Nayak A; Hanna MG; Fang Y; Peng X; Yan L; Li X; Fadare O; Ambrosone C
• Folate Receptor-alpha (FR alpha), Glycoprotein Nonmetastatic Melanoma B (GPNMB), BRCA1 Associated Protein (BAP1) and beta-Catenin Are Highly Expressed in Triple Negative Breast Carcinoma
  Volume: 31 Page(s): 82 - 82
  03/01/2018 Authors: Krishnamurti U; Yang J; Peng L; Cohen C; Li X
• CDK9 Expression Shows Role as a Potential Prognostic Biomarker in Breast Cancer Patients Who Fail to Achieve Pathologic Complete Response after Neoadjuvant Chemotherapy.
  Int J Breast Cancer Volume: 2018 Page(s): 6945129
  01/01/2018 Authors: Schlafstein AJ; Withers AE; Rudra S; Danelia D; Switchenko JM; Mister D; Harari S; Zhang H; Daddacha W; Ehdaivand S
• African American patients with breast cancer have worse prognosis than white patients in certain subtypes and stages.
  Breast Cancer Res Treat Volume: 166 Page(s): 743 - 755
  12/01/2017 Authors: Arciero CA; Yang J; Peng L; Ward KC; O'Regan R; Sahin AA; Li X
• Comparison of Oncotype DX With Modified Magee Equation Recurrence Scores in Low-Grade Invasive Carcinoma of Breast.
  Am J Clin Pathol Volume: 148 Page(s): 167 - 172
  08/01/2017 Authors: Hou Y; Zynger DL; Li X; Li Z
• Hormone Receptor-Positive Breast Cancer HasaWorse Prognosis in Male Than in FemalePatients.
  Clin Breast Cancer Volume: 17 Page(s): 356 - 366
  08/01/2017 Authors: Li X; Yang J; Krishnamurti U; Huo L; Ward KC; O'Regan R; Peng L
• High tumor budding count is associated with adverse clinicopathologic features and poor prognosis in breast carcinoma.
  Volume: 66 Page(s): 222 - 229
  08/01/2017 Authors: Li X; Wei B; Sonmez C; Li Z; Peng L
• Role of RPL39 in Metaplastic Breast Cancer.
  J Natl Cancer Inst Volume: 109
  06/01/2017 Authors: Dave B; Gonzalez DD; Liu Z-B; Li X; Wong H; Granados S; Ezzedine NE; Sieglaff DH; Ensor JE; Miller KD
• Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers.
  Hum Pathol Volume: 64 Page(s): 7 - 12
  06/01/2017 Authors: Krishnamurti U; Wetherilt CS; Yang J; Peng L; Li X
• HER3-EGFR score to predict clinical outcomes in triple-negative breast cancer.
  Volume: 35
  05/20/2017 Authors: Ogden A; Bhattarai S; Green AR; Aleskandarany MA; Rakha EA; Ellis IO; Li XB; Krishnarnurti U; Janssen EA; Jonsdottir K
• New Developments in Breast Cancer and Their Impact on Daily Practice in Pathology.
  Arch Pathol Lab Med Volume: 141 Page(s): 490 - 498
  04/01/2017 Authors: Li X; Oprea-Ilies GM; Krishnamurti U
• Multi-institutional study of nuclear KIFC1 as a biomarker of poor prognosis in African American women with triple-negative breast cancer.
  Sci Rep Volume: 7 Page(s): 42289
  02/20/2017 Authors: Ogden A; Garlapati C; Li XB; Turaga RC; Oprea-Ilies G; Wright N; Bhattarai S; Mittal K; Wetherilt CS; Krishnamurti U
• Triple Negative Breast Cancer Has Worse Overall Survival and Cause-Specific Survival Than Non-Triple Negative Breast Cancer
  Volume: 97 Page(s): 54A - 54A
  02/01/2017 Authors: Li X; Yang J; Peng L; Sahin AA; Huo L; Ward KC; O'Regan R; Torres MA; Meisel JL
• Pathological Prognostic Factors in Estrogen Receptor Positive/Her2 Negative and Lymph Node Negative Breast Cancers
  Volume: 30 Page(s): 59A - 59A
  02/01/2017 Authors: Mendoza P; Sonmez C; Zhang C; Neely C; Liu Y; Li X
• Low Progesterone Receptor Expression Is Associated with Distant Metastasis in Estrogen Receptor Positive/HER2 Negative and Lymph Node Negative Breast Cancer
  Volume: 30 Page(s): 59A - 59A
  02/01/2017 Authors: Mendoza P; Sonmez C; Neely C; Zhang C; Liu Y; Li X
• Pathological Prognostic Factors in Estrogen Receptor Positive/Her2 Negative and Lymph Node Negative Breast Cancers
  Volume: 97 Page(s): 59A - 59A
  02/01/2017 Authors: Mendoza P; Sonmez C; Zhang C; Neely C; Liu Y; Li X
• Discrepancy Among Oncotype DX Testing, Immunohistochemistry, and Fluorescence In-Situ Hybridization Methods in Evaluating Breast Cancer Biomarker Status
  Volume: 97 Page(s): 56A - 56A
  02/01/2017 Authors: Logan SJ; Zhang C; Liu Y; Siddiqui MT; Cohen C; Li X
• Low Progesterone Receptor Expression Is Associated with Distant Metastasia in Estrogen Receptor Positive/HER2 Negative and Lymph Node Negative Breast Cancer
  Volume: 97 Page(s): 59A - 59A
  02/01/2017 Authors: Mendoza P; Sonmez C; Neely C; Zhang C; Liu Y; Li X
• Estrogen Receptor-Positive/HER2-Negative and Lymph Node-Negative Breast Cancers Have Similar Oncotype DX Recurrence Score Distribution and Prognosis in African American and Caucasian Patients
  Volume: 97 Page(s): 56A - 57A
  02/01/2017 Authors: Logan SJ; Zhang C; Liu Y; Siddiqui MT; Cohen C; Li X
• Ki-67 Score Is Not Predictive of Overall Survival, Disease-Free Survival or Metastasis in Estrogen Receptor Positive, Her2 Negative, Lymph Node Negative Breast Cancers
  Volume: 97 Page(s): 46A - 46A
  02/01/2017 Authors: Hiskey M; Mendoza P; Neely C; Sonmez C; Zhang C; Liu Y; Siddiqui MT; Cohen C; Li X
• Lymph Node Metastasis Is Not Predictive of Overall Survival, Disease Free Survival, or Metastasis in Estrogen Receptor-Positive/Her2-Negative Breast Cancer
  Volume: 30 Page(s): 57A - 57A
  02/01/2017 Authors: Logan SJ; Sonmez C; Zhang C; Neely C; Mendoza P; Arciero C; Liu Y; Li X
• Phase 2 trial of everolimus and/or trastuzumab in hormone refractory, hormone receptor (HR)-positive, HER2-normal metastatic breast cancer (MBC)
  Volume: 77
  02/01/2017 Authors: Paplomata E; Gogineni K; Meisel J; Santa-Maria C; Yuan L; Kramer J; Li XB; Zelnak A; Pakkala S; Kaklamani V
• NRG oncology/NSABP B-51/RTOG 1304: A phase III superiority clinical trial designed to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to breast RT post breast-conserving surgery (BCS) will reduce invasive cancer events in patients (pts) with positive axillary (Ax) nodes and convert to ypN0 after neoadjuvant chemotherapy (NC)
  Volume: 77
  02/01/2017 Authors: Mamounas EP; Bandos H; White JR; Julian TB; Khan AJ; Shaitelman SF; Torres MA; Vicini FA; Ganz PA; McCloskey SA
• Triple Negative Breast Cancer Has Worse Overall Survival and Cause-Specific Survival Than Non-Triple Negative Breast Cancer
  Volume: 30 Page(s): 54A - 54A
  02/01/2017 Authors: Li X; Yang J; Peng L; Sahin AA; Huo L; Ward KC; O'Regan R; Torres MA; Meisel JL
• High Tumor Budding Count Is Associated with Poor Clinicopathological Features and Prognosis in Breast Carcinoma
  Volume: 30 Page(s): 72A - 72A
  02/01/2017 Authors: Sonmez C; Logan SJ; Wei B; Peng L; Krishnamurti U; Li X
• Estrogen Receptor-Positive/HER2-Negative and Lymph Node-Negative Breast Cancers Have Similar Oncotype DX Recurrence Score Distribution and Prognosis in African American and Caucasian Patients
  Volume: 30 Page(s): 56A - 57A
  02/01/2017 Authors: Logan SJ; Zhang C; Liu Y; Siddiqui MT; Cohen C; Li X
• Discrepancy Among Oncotype DX Testing, Immunohistochemistry, and Fluorescence In-Situ Hybridization Methods in Evaluating Breast Cancer Biomarker Status
  Volume: 30 Page(s): 56A - 56A
  02/01/2017 Authors: Logan SJ; Zhang C; Liu Y; Siddiqui MT; Cohen C; Li X
• Ki-67 Score Is Not Predictive of Overall Survival, Disease-Free Survival or Metastasis in Estrogen Receptor Positive, Her2 Negative, Lymph Node Negative Breast Cancers
  Volume: 30 Page(s): 46A - 46A
  02/01/2017 Authors: Hiskey M; Mendoza P; Neely C; Sonmez C; Zhang C; Liu Y; Siddiqui MT; Cohen C; Li X
• Lymph Node Metastasis Is Not Predictive of Overall Survival, Disease Free Survival, or Metastasis in Estrogen Receptor-Positive/Her2-Negative Breast Cancer
  Volume: 97 Page(s): 57A - 57A
  02/01/2017 Authors: Logan SJ; Sonmez C; Zhang C; Neely C; Mendoza P; Arciero C; Liu Y; Li X
• Targeted drugs and diagnostic assays: Companions in the race to combat ethnic disparity.
  Front Biosci (Landmark Ed) Volume: 22 Page(s): 193 - 211
  01/01/2017 Authors: Wright N; Rida P; Krishnamurti U; Li X; Aneja R
• Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer.
  Breast Cancer Res Treat Volume: 161 Page(s): 279 - 287
  01/01/2017 Authors: Li X; Yang J; Peng L; Sahin AA; Huo L; Ward KC; O'Regan R; Torres MA; Meisel JL
• Distinctions in Breast Tumor Recurrence Patterns Post-Therapy among Racially Distinct Populations.
  PLoS One Volume: 12 Page(s): e0170095
  01/01/2017 Authors: Wright N; Xia J; Cantuaria G; Klimov S; Jones M; Neema P; Il'yasova D; Krishnamurti U; Li X; Reid MD
• Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer.
  Am J Clin Pathol Volume: 146 Page(s): 496 - 502
  10/01/2016 Authors: Li X; Wetherilt CS; Krishnamurti U; Yang J; Ma Y; Styblo TM; Meisel JL; Peng L; Siddiqui MT; Cohen C
• Anti-3-18F-FACBC (18F-Fluciclovine) PET/CT of Breast Cancer: An Exploratory Study.
  J Nucl Med Volume: 57 Page(s): 1357 - 1363
  09/01/2016 Authors: Tade FI; Cohen MA; Styblo TM; Odewole OA; Holbrook AI; Newell MS; Savir-Baruch B; Li X; Goodman MM; Nye JA
• Estrogen Receptor and Cytokeratin 5 Are Reliable Markers to Separate Usual Ductal Hyperplasia From Atypical Ductal Hyperplasia and Low-Grade Ductal Carcinoma In Situ.
  Arch Pathol Lab Med Volume: 140 Page(s): 686 - 689
  07/01/2016 Authors: Martinez AP; Cohen C; Hanley KZ; Li XB
• Biomarkers Predicting Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer.
  Volume: 145 Page(s): 871 - 878
  06/01/2016 Authors: Li XB; Krishnamurti U; Bhattarai S; Klimov S; Reid MD; O'Regan R; Aneja R
• A multi-institutional study of racial differences in androgen receptor status among triple-negative breast cancers.
  Volume: 34
  05/20/2016 Authors: Bhattarai S; Xia J; Wetherilt CS; Pattni S; Klimov S; Riaz A; Aleskandarany M; Green AR; Rakha E; Ellis IO
• A combined HER3-EGFR score in triple-negative breast cancer: racial differences.
  Volume: 34
  05/20/2016 Authors: Ogden A; Bhattarai S; Wright N; Klimov S; Pattni S; Aleskandarany M; Green AR; Rakha E; Ellis IO; Li X
• Multi-institutional study of triple negative breast cancer stratification by a metric that quantifies cell cycling kinetics.
  Volume: 34
  05/20/2016 Authors: Klimov S; Wei G; Green AR; Aleskandarany M; Rakha E; Ellis IO; Cantuaria GH; Agboola A; Reid MD; Li X
• An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model.
  Genes Dev Volume: 30 Page(s): 918 - 930
  04/15/2016 Authors: Jennis M; Kung C-P; Basu S; Budina-Kolomets A; Leu JI-J; Khaku S; Scott JP; Cai KQ; Campbell MR; Porter DK
• Sensitivity of triple-negative breast cancer cell lines to cytotoxic and targeted agents as a function of molecular subtype
  Volume: 25
  03/01/2016 Authors: Colley H; Saxena R; Ogden A; Cantuaria G; Reid MD; Li XB; Krishnamurthy U; Rida PCG; Aneja R
• Management of Benign Papilloma of the Breast Diagnosed on Core Biopsy, a Review of 4182 Cases
  Volume: 29 Page(s): 54A - 54A
  02/01/2016 Authors: Li XB
• Retinoic Acid Receptor Alpha Is a Positive Prognostic Biomarker in Triple-Negative Breast Cancer
  Volume: 29 Page(s): 62A - 63A
  02/01/2016 Authors: Ogden A; Green A; Aleskandarany MA; Rakha E; Ellis IO; Ali S; Li X; Krishnamurti U; Reid MD; Rida PCG
• Management of Benign Papilloma of the Breast Diagnosed on Core Biopsy, a Review of 4182 Cases
  Volume: 96 Page(s): 54A - 54A
  02/01/2016 Authors: Li XB
• High HER3-EGFR Score Predicts Aggressive Disease Course in Triple-Negative Breast Cancer
  Volume: 29 Page(s): 63A - 63A
  02/01/2016 Authors: Ogden A; Green A; Aleskandarany MA; Rakha E; Ellis IO; Li X; Krishnamurti U; Reid MD; Rida PCG; Aneja R
• Validation of Modified Magee Equation to Predict the Oncotype DX Recurrence Score
  Volume: 96 Page(s): 61A - 62A
  02/01/2016 Authors: Neely C; Yang J; Bhattarai S; Peng L; Krishnamurti U; Aneja R; Li X
• High Peripheral Stromal Lymphocytic Infiltration Is Associated with Better Survival in Triple Negative Breast Carcinoma
  Volume: 96 Page(s): 52A - 52A
  02/01/2016 Authors: Krishnamurti U; Sonmez C; Yang J; Peng L; Li X; Aneja R
• Male Breast Carcinoma Has Worse Prognosis Than Female Breast Carcinoma
  Volume: 96 Page(s): 54A - 54A
  02/01/2016 Authors: Li XB; Krishnamurti U; Huo L; Peng L
• Retinoic Acid Receptor Alpha Is a Positive Prognostic Biomarker in Triple-Negative Breast Cancer
  Volume: 96 Page(s): 62A - 63A
  02/01/2016 Authors: Ogden A; Green A; Aleskandarany MA; Rakha E; Ellis IO; Ali S; Li X; Krishnamurti U; Reid MD; Rida PCG
• High HER3-EGFR Score Predicts Aggressive Disease Course in Triple-Negative Breast Cancer
  Volume: 96 Page(s): 63A - 63A
  02/01/2016 Authors: Ogden A; Green A; Aleskandarany MA; Rakha E; Ellis IO; Li X; Krishnamurti U; Reid MD; Rida PCG; Aneja R
• Male Breast Carcinoma Has Worse Prognosis Than Female Breast Carcinoma
  Volume: 29 Page(s): 54A - 54A
  02/01/2016 Authors: Li XB; Krishnamurti U; Huo L; Peng L
• High Peripheral Stromal Lymphocytic Infiltration Is Associated with Better Survival in Triple Negative Breast Carcinoma
  Volume: 29 Page(s): 52A - 52A
  02/01/2016 Authors: Krishnamurti U; Sonmez C; Yang J; Peng L; Li X; Aneja R
• Validation of Modified Magee Equation to Predict the Oncotype DX Recurrence Score
  Volume: 29 Page(s): 61A - 62A
  02/01/2016 Authors: Neely C; Yang J; Bhattarai S; Peng L; Krishnamurti U; Aneja R; Li X
• Biomarkers Predicting Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer
  Volume: 29 Page(s): 54A - 54A
  02/01/2016 Authors: Li XB; Krishnamurti U; Bhattarai S; Klimov S; Reid M; Aneja R
• Epithelioid sarcoma of the vulva and its clinical implication: A case report and review of the literature.
  Gynecol Oncol Rep Volume: 15 Page(s): 31 - 33
  01/01/2016 Authors: Han CH; Li X; Khanna N
• GATA-3 and FOXA1 expression is useful to differentiate breast carcinoma from other carcinomas.
  Hum Pathol Volume: 47 Page(s): 26 - 31
  01/01/2016 Authors: Davis DG; Siddiqui MT; Oprea-Ilies G; Stevens K; Osunkoya AO; Cohen C; Li XB
• A novel metric to quantify cell-cycling kinetics and refine the Nottingham Grading System to improve breast cancer patient stratification
  Volume: 33
  05/20/2015 Authors: Klimov S; Pannu V; Wright N; Osan R; Cantuaria GH; Wells S; Li X; Reid MD; Rida PCG; Aneja R
• Consequences of passages: Mitotic indices and centrosome amplification levels variance between patients' tumors and cancer cells cultured in vitro.
  Volume: 33
  05/20/2015 Authors: Pannu V; Donthamsetty S; Mittal K; Rida PCG; Cantuaria GH; Reid MD; Li X; Aneja R
• A novel prognostic index to improve patient stratification compared to the Nottingham grading system
  Volume: 33
  05/20/2015 Authors: Shin H; Klimov S; Cantuaria GH; Li X; Rida PCG; Osan R; Aneja R
• Preliminary findings of anti-[F-18] FACBC (FACBC) PET-CT imaging of breast cancer
  Volume: 56
  05/01/2015 Authors: Tade F; Odewole O; Cohen M; Styblo T; Li X; Holbrook A; Newell M; Savir-Baruch B; Goodman M; Schuster D
• Rampant centrosome amplification underlies more aggressive disease course of triple negative breast cancers.
  Oncotarget Volume: 6 Page(s): 10487 - 10497
  04/30/2015 Authors: Pannu V; Mittal K; Cantuaria G; Reid MD; Li X; Donthamsetty S; McBride M; Klimov S; Osan R; Gupta MV
• High pathologic complete response in Her2-positive, early-stage breast cancer to a novel nonanthracycline neoadjuvant chemotherapy.
  Clin Breast Cancer Volume: 15 Page(s): 31 - 36
  02/01/2015 Authors: Zelnak AB; Nikolinakos P; Srinivasiah J; Jonas W; Pippas A; Liu Y; Li X; Torres M; O'Regan RM; Georgia Center for Oncology Research and Education
• Positive GATA-3 and FOXA1 Expression Is Useful To Differentiate Breast Carcinoma From Other Carcinomas
  Volume: 95 Page(s): 41A - 41A
  02/01/2015 Authors: Davis D; Siddiqui M; Oprea-Ilies G; Osunkoya A; Cohen C; Li X
• HER2 Positivity, High Mitotic Rate, and Tumor Grade Are Associated With Pathologic Complete Response To Neoadjuvant Therapy in Breast Cancer
  Volume: 95 Page(s): 63A - 63A
  02/01/2015 Authors: Robinson B; O'Regan R; Styblo T; Li X
• Positive GATA-3 and FOXA1 Expression Is Useful To Differentiate Breast Carcinoma From Other Carcinomas
  Volume: 28 Page(s): 41A - 41A
  02/01/2015 Authors: Davis D; Siddiqui M; Oprea-Ilies G; Osunkoya A; Cohen C; Li X
• HER2 Positivity, High Mitotic Rate, and Tumor Grade Are Associated With Pathologic Complete Response To Neoadjuvant Therapy in Breast Cancer
  Volume: 28 Page(s): 63A - 63A
  02/01/2015 Authors: Robinson B; O'Regan R; Styblo T; Li X
• Phospho-Histone H3 Stain Increases Inter-Observer Reproducibility and Is More Efficient Than H&E Stain To Evaluate Mitotic Index in Breast Cancer
  Volume: 28 Page(s): 518A - 518A
  02/01/2015 Authors: Li X; Wells S; Cantuaria G; Pannu V; Wright N; Klimov S; Rida P; Aneja R; Reid M
• Phospho-Histone H3 Stain Increases Inter-Observer Reproducibility and Is More Efficient Than H&E Stain To Evaluate Mitotic Index in Breast Cancer
  Volume: 95 Page(s): 518A - 518A
  02/01/2015 Authors: Li X; Wells S; Cantuaria G; Pannu V; Wright N; Klimov S; Rida P; Aneja R; Reid M
• Targeting RPL39 and MLF2 reduces tumor initiation and metastasis in breast cancer by inhibiting nitric oxide synthase signaling.
  Proc Natl Acad Sci U S A Volume: 111 Page(s): 8838 - 8843
  06/17/2014 Authors: Dave B; Granados-Principal S; Zhu R; Benz S; Rabizadeh S; Soon-Shiong P; Yu K-D; Shao Z; Li X; Gilcrease M
• Triple Negative Breast Cancers Lack Nuclear FOX1 Expression
  Volume: 27 Page(s): 64A - 65A
  02/01/2014 Authors: Li X; Smith GH; Castaneda-Valladares FE; Giri MJ; Orea-Ilies GM; Cohen C
• Triple Negative Breast Cancers Lack Nuclear FOX1 Expression
  Volume: 94 Page(s): 64A - 65A
  02/01/2014 Authors: Li X; Smith GH; Castaneda-Valladares FE; Giri MJ; Oprea-Ilies GM; Cohen C
• Prognostic Significance of Multifocal Lesion in ER plus Breast Cancers
  Volume: 27 Page(s): 65A - 65A
  02/01/2014 Authors: Liang Y; Li X; Wang J; Huo L; Albarracin C; Gong Y; Wu Y
• Prognostic Significance of Multifocal Lesion in ER plus Breast Cancers
  Volume: 94 Page(s): 65A - 65A
  02/01/2014 Authors: Liang Y; Li X; Wang J; Huo L; Albarracin C; Gong Y; Wu Y
• Diagnostic utility of E-cadherin and P120 catenin cocktail immunostain in distinguishing DCIS from LCIS.
  Int J Clin Exp Pathol Volume: 7 Page(s): 2551 - 2557
  01/01/2014 Authors: Li X; Schwartz MR; Ro J; Hamilton CR; Ayala AG; Truong LD; Zhai QJ
• The effect of prolonged cold ischemia time on estrogen receptor immunohistochemistry in breast cancer.
  Mod Pathol Volume: 26 Page(s): 71 - 78
  01/01/2013 Authors: Li X; Deavers MT; Guo M; Liu P; Gong Y; Albarracin CT; Middleton LP; Huo L
• Adenoid Cystic Carcinoma of the Breast: Clinicopathologic and Molecular Analysis of 56 Cases
  Volume: 92 Page(s): 76A - 77A
  02/01/2012 Authors: Zhu X; Chen J; Xing Y; Albarracin CT; Zhao Y; Rao PH; Li X; Bell D; El-Naggar A; Abraham SC
• Adenoid Cystic Carcinoma of the Breast: Clinicopathologic and Molecular Analysis of 56 Cases
  Volume: 25 Page(s): 76A - 77A
  02/01/2012 Authors: Zhu X; Chen J; Xing Y; Albarracin CT; Zhao Y; Rao PH; Li X; Bell D; El-Naggar A; Abraham SC
• A Cocktail of E-Cadherin and p120 Catenin Reliably Distinguishes DCIS From LCIS
  Volume: 134 Page(s): 678 - 678
  10/01/2010 Authors: Li XW; Schwartz MR; Truong L; Ayala AG; Ro JY; Zhai QJ
• High pathologic complete response (pCR) in HER2-positive breast cancer to novel nonanthracycline neoadjuvant chemotherapy.
  JOURNAL OF CLINICAL ONCOLOGY Volume: 28
  05/20/2010 Authors: Zelnak AB; Leyland-Jones B; Gabram-Mendola S; Styblo TM; Rizzo M; Wood WC; Srinivasiah J; Jonas WS; Schnell FM; O'Regan R
• Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features.
  Proc Natl Acad Sci U S A Volume: 106 Page(s): 13820 - 13825
  08/18/2009 Authors: Creighton CJ; Li X; Landis M; Dixon JM; Neumeister VM; Sjolund A; Rimm DL; Wong H; Rodriguez A; Herschkowitz JI
• Efficient generation of primary xenografts using normal and malignant human mammary epithelium in SCID/Beige mice without humanizing fibroblasts
  Volume: 69
  05/01/2009 Authors: Zhang X; Huang J; Lai Q; Li X; Moraes R; Wong H; Wiechmann L; Schiff R; Cristofanilli M; Krishnamurthy S
• An unusually large granular cell tumor of the pharynx: a case report and literature review.
  Int J Clin Exp Pathol Volume: 2 Page(s): 300 - 302
  01/01/2009 Authors: Li X; Parke RB; Rushton JR; Sienko A; Zhai QJ
• Gene signature of cancer stem cells in an intrinsic subgroup of breast cancers with mesenchymal properties
  JOURNAL OF CLINICAL ONCOLOGY Volume: 26
  05/20/2008 Authors: Chang JC; Creighton C; Landis M; Lewis MT; Li X; Pavlick A; Rosen J; Perou CM; Rosen J
• Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.
  J Natl Cancer Inst Volume: 100 Page(s): 672 - 679
  05/07/2008 Authors: Li X; Lewis MT; Huang J; Gutierrez C; Osborne CK; Wu M-F; Hilsenbeck SG; Pavlick A; Zhang X; Chamness GC
• Breast cancer tumorigenic cells are resistant to chemotherapy
  Volume: 88 Page(s): 43A - 43A
  01/01/2008 Authors: Li X; Lewis MT; Creighton C; Wong H; Gutierrez MC; Osborne CK; Hilsenbeck SG; Rosen J; Zhai QJ; Schwartz MR
• Breast cancer tumorigenic cells are resistant to chemotherapy
  Volume: 21 Page(s): 43A - 43A
  01/01/2008 Authors: Li X; Lewis MT; Creighton C; Wong H; Gutierrez MC; Osborne CK; Hilsenbeck SG; Rosen J; Zhai QJ; Schwartz MR
• Decrease in tumorigenic breast cancer stem cells in primary breast cancers with neoadjuvant lapatinib.
  Volume: 106 Page(s): S22 - S23
  12/01/2007 Authors: Li X; Creighton C; Wong H; Hilsenbeck SG; Osborne CK; Rosen JM; Lewis MT; Chang JC
• Avicins, a novel plant-derived metabolite lowers energy metabolism in tumor cells by targeting the outer mitochondrial membrane.
  Mitochondrion Volume: 7 Page(s): 234 - 240
  05/01/2007 Authors: Haridas V; Li X; Mizumachi T; Higuchi M; Lemeshko VV; Colombini M; Gutterman JU
• Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype.
  Clin Cancer Res Volume: 12 Page(s): 5047 - 5054
  09/01/2006 Authors: Nguyen DM; Sam K; Tsimelzon A; Li X; Wong H; Mohsin S; Clark GM; Hilsenbeck SG; Elledge RM; Allred DC
• The codon 47 polymorphism in p53 is functionally significant.
  J Biol Chem Volume: 280 Page(s): 24245 - 24251
  06/24/2005 Authors: Li X; Dumont P; Della Pietra A; Shetler C; Murphy ME
• Proapoptotic triterpene electrophiles (avicins) form channels in membranes: cholesterol dependence.
  Biophys J Volume: 88 Page(s): 2577 - 2584
  04/01/2005 Authors: Li XX; Davis B; Haridas V; Gutterman JU; Colombini M
• Catalyzed insertion of proteins into phospholipid membranes: specificity of the process.
  Biophys J Volume: 83 Page(s): 2550 - 2559
  11/01/2002 Authors: Li XX; Colombini M
• Electrostatics explains the shift in VDAC gating with salt activity gradient.
  Biophys J Volume: 82 Page(s): 1773 - 1783
  04/01/2002 Authors: Levadny V; Colombini M; Li XX; Aguilella VM
• Bcl-xL promotes the open configuration of the voltage-dependent anion channel and metabolite passage through the outer mitochondrial membrane.
  J Biol Chem Volume: 276 Page(s): 19414 - 19419
  06/01/2001 Authors: Vander Heiden MG; Li XX; Gottleib E; Hill RB; Thompson CB; Colombini M
• Outer mitochondrial membrane permeability can regulate coupled respiration and cell survival.
  Proc Natl Acad Sci U S A Volume: 97 Page(s): 4666 - 4671
  04/25/2000 Authors: Vander Heiden MG; Chandel NS; Li XX; Schumacker PT; Colombini M; Thompson CB
• The specificity of auto-directed insertion
  BIOPHYSICAL JOURNAL Volume: 78 Page(s): 31A - 31A
  01/01/2000 Authors: Li X; Colombini M